Safety and immunogenicity of recombinant, live attenuated tetravalent dengue vaccine (CYD- TDV) in healthy Vietnamese adults and children

Journal of Vaccines and Vaccination

Volumn 3, Issue 7, 2012, Pages

  Tran, Ngoc Huu ^a   Luong, Chan Quang ^a   Vu, Thi Que Huong ^a   Forrat, Remi ^b   Lang, Jean ^b   Vu, Quoc Dat ^c   Bouckenooghe, Alain ^c   Wartel, Tram Anh ^d  

^a PASTEUR INSTITUTE   (Viet Nam)

^b SANOFI PASTEUR   (France)

^c Sanofi Pasteur R and D ^*  (Singapore)

^d Clinical R and D   (Thailand)

Author keywords

CYD TDV dengue vaccine; Dengue; Immunogenicity; Live attenuated tetravalent; Phase II trial; Recombinant vaccine; Safety

Indexed keywords

EID: 84875697878     PISSN: None     EISSN: 21577560     Source Type: Journal    
DOI: 10.4172/2157-7560.1000162     Document Type: Article

References (22)

1. World Health Organization (2012) Dengue and severe dengue, Fact sheet N°117.
2. World Health Organization Regional Office for South-East Asia (2011) Comprehensive Guidelines for Prevention and Control of Dengue and Dengue Haemorrhagic Fever.
3. Guzman A, Isturiz RE (2010) Update on the global spread of dengue. Int J Antimicrob Agents 36: 40-42.
4. Lam SK, Burke D, Capeding MR, Chong CK, Coudeville L, et al. (2011) Preparing for introduction of a dengue vaccine: Recommendations from the 1st Dengue v2V Asia-Pacific Meeting. Vaccine 28: 9417-9422.
5. Guy B, Barrere B, Malinowski C, Saville M, Teyssou R, et al. (2011) From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 29: 7229-7241.
6. World Health Organization (2003) WHO TRS 932 Guideline for the production and quality control of candidate tetravalent dengue vaccines.
7. World Health Organization (2008) Guidelines for the clinical evaluation of dengue vaccine in endemic areas, WHO/IVB/08.12.
8. World Health Organization (2007) Guidelines for plaque reduction neutralization testing of human antibodies to dengue viruses, WHO/IVB/07.07.
9. World Health Organization. Regional Office for South-East Asia and for the Western Pacific, Health in Asia and the Pacific 2008, New Delhi, India. WHO Regional Office for South-East Asia: 539.
10. Tien NT, Luxemburger C, Toan NT, Pollissard-Gadroy L, Huong VT, et al. (2010) A prospective cohort study of dengue infection in schoolchildren in Long Xuyen, Viet Nam. Trans R Soc Trop Med Hyg 104: 592-600.
11. Ha DQ, Tien NT, Huong VT, Loan HT, Thang CM (1998) Dengue epidemic in southern Vietnam. Emerg Infect Dis 6: 422-425.
12. Vu TT, Holmes EC, Duong V, Nguyen TQ, Tran TH, et al. (2010) Emergence of the Asian 1 genotype of dengue virus serotype 2 in Vietnam: in vivo fitness advantage and lineage replacement in South-East Asia. PLoS Negl Trop Dis 4: 757.
13. Yen NT, Duffy MR, Hong NM, Hien NT, Fischer M, et al. (2010) Surveillance for Japanese encephalitis in Vietnam, 1998-2007. Am J Trop Med Hyg 83: 816-819.
14. Nasveld PE, Ebringer A, Elmes N, Bennett S, Yoksan S, et al. (2010) Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccine: randomized, double-blind, 5-year phase II study in healthy adults. Hum Vaccin 6: 1038-1046.
15. World Health Organization (1997) Dengue Haemorrhagic Fever, Diagnosis, Treatment, Prevention and Control (2ndedn), WHO, Geneva.
16. Capeding RZ, Luna IA, Bomasang E, Lupisan S, Lang J, et al. (2011) Liveattenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines. Vaccine 29: 3863-3872.
17. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, et al. (2012) Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 380: 1559-1567.
18. Sin Leo Y, Wilder-Smith A, Archuleta S, Shek L, Chong CY, et al. (2012) Immunogenicity and safety of recombinant tatravalent dengue vaccine (CYDTDV) in individuals aged 2-45 y. Hum Vaccin Immunother 8.
19. Lanata CF, Andrade T, Gil AI, Terrones C, Valladolid O, et al. (2012) Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: Randomized, controlled, phase II study in Piura, Peru. Vaccine 30: 5935-5941.
20. Poo J, Galan F, Forrat R, Zambrano B, Lang J, et al. (2010) Live-attenuated Tetravalent Dengue Vaccine in Dengue-naive Children, Adolescents, and Adults in Mexico City: Randomized Controlled Phase 1 Trial of Safety and Immunogenicity. Pediatr Infect Dis J.
21. Morrison D, Legg TJ, Billings CW, Forrat R, Yoksan S, et al. (2010) A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirusnaive adults. J Infect Dis 201: 370-377.
22. Guy B, Saville M, Lang J (2010) Development of Sanofi Pasteur tetravalent dengue vaccine. Hum Vaccin 6.